STOCK TITAN

QTREX Announces Pricing of a $10 Million Registered Direct Offering of Ordinary Shares

(Neutral)
Tags

QTREX Quantum (Nasdaq: QTEX) entered into a definitive securities purchase agreement with an existing and a new global institutional investor to sell 11,111,111 ordinary shares in a registered direct offering. Gross proceeds are expected to be about $10 million before fees and expenses, with closing anticipated on or about August 21, 2026, subject to customary conditions.

According to QTREX Quantum, net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent, and the shares are being issued under an effective Form F-3 shelf registration statement via a prospectus supplement and base prospectus filed with the SEC.

Loading...
Loading translation...

Positive

  • Registered direct offering to raise gross proceeds of about $10 million
  • 11,111,111 ordinary shares placed with existing and new institutional investors
  • Use of effective Form F-3 shelf enables relatively quick access to equity capital

Negative

  • Issuance of 11,111,111 new ordinary shares implies equity dilution for existing shareholders
  • Net cash received will be lower than the stated $10 million gross proceeds due to fees and expenses

News Explained

If the announced offering closes, QTREX Quantum would issue 11,111,111 ordinary shares, increasing the total share count and reducing existing holders’ percentage ownership; the approximately $10 million gross proceeds are before fees and expenses.

Market Context

The tag-specific record contains one prior offering reaction of -8.7% over 24 hours, providing a dir...
Analysis

The tag-specific record contains one prior offering reaction of -8.7% over 24 hours, providing a direct comparison for this financing. The active F-3 shelf adds financing context; investors could watch closing completion and subsequent filings.

Key Figures

Gross proceeds: $10 million Shares offered: 11,111,111 ordinary shares Expected closing: August 21, 2026 +1 more
4 metrics
Gross proceeds $10 million Registered direct offering, before fees and expenses
Shares offered 11,111,111 ordinary shares Registered direct offering
Expected closing August 21, 2026 Subject to customary closing conditions
Shelf effectiveness date December 12, 2025 Form F-3 shelf registration statement

Previous Offering Reports

1 past event · Latest: Dec 15 (Negative)
Same Type Pattern 1 events
Date Event Sentiment 24h Move Catalyst
Dec 15 Registered offering Negative -8.7% Registered direct offering produced $1.8 million in gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The tag-specific prior offering was followed by -8.7% over 24 hours, aligning with a negative financing-related reaction pattern.

Key Terms

registered direct offering, shelf registration statement, form f-3, prospectus supplement
4 terms
registered direct offering financial
"entered into a definitive securities purchase agreement ... in a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
shelf registration statement regulatory
"in connection with a takedown from the Company’s shelf registration statement"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
form f-3 regulatory
"shelf registration statement on Form F-3"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
prospectus supplement regulatory
"pursuant to a prospectus supplement to be filed with the Securities and Exchange Commission"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

The financing was led by continued support of an existing institutional investor along with participation from a new global institutional investor

Ness Ziona, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics for quantum computing infrastructure, today announced that it has entered into a definitive securities purchase agreement with an existing institutional investor as well as a new global institutional investor for the purchase and sale of 11,111,111 ordinary shares in a registered direct offering (the "Offering"). The gross proceeds to the Company from the Offering are expected to be approximately $10 million, before deducting placement agent fees and other estimated offering expenses.

The closing of the Offering is expected to occur on or about August 21, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

The Offering includes continued participation from a prominent global institutional investor  alongside a new institutional investor that is part of a well-established global investment management firm with a multi-decade track record.

A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering.

The ordinary shares  are being offered and sold pursuant to a prospectus supplement to be filed with the Securities and Exchange Commission (“SEC”) in connection with a takedown from the Company’s shelf registration statement on Form F-3 (File No. 333-289324), including a base prospectus, previously filed with the SEC on August 6, 2025, as amended on November 25, 2025, which was declared effective by the SEC on December 12, 2025. The Offering is being made only by means of a prospectus supplement and accompanying prospectus which are a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying prospectus may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About QTREX Quantum

QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.

For more information, please visit: www.q-trex.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the receipt and use of proceeds from the Offering; and the filing of a prospectus supplement and the accompanying prospectus relating to the Offering.  Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements. More detailed information about the risks and uncertainties affecting the Company is contained under "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on March 26, 2026.

Company Contact

QTREX Quantum

Email: info@q-trex.com

Phone: +972-9-9664485



Company Contact
QTREX Quantum
Email: info@q-trex.com
Phone: +972-9-9664485

FAQ

What did QTREX Quantum (Nasdaq: QTEX) announce on August 20, 2026?

QTREX Quantum announced a registered direct offering of 11,111,111 ordinary shares, expecting about $10 million in gross proceeds. According to QTREX Quantum, the deal involves an existing institutional investor and a new global institutional investor, with closing targeted around August 21, 2026, subject to customary conditions.

How much money will QTREX Quantum (QTEX) raise in its August 2026 registered direct offering?

QTREX Quantum expects gross proceeds of approximately $10 million from its August 2026 registered direct offering. According to QTREX Quantum, this amount is before deducting placement agent fees and other offering expenses, so net proceeds available for corporate use will be lower than the stated gross figure.

How many new QTEX ordinary shares are being issued in QTREX Quantum's August 2026 offering?

QTREX Quantum plans to issue 11,111,111 new ordinary shares in the August 2026 registered direct offering. According to QTREX Quantum, these shares are being sold to an existing institutional investor and a new global institutional investor under an effective Form F-3 shelf registration statement.

When is QTREX Quantum's (QTEX) August 2026 registered direct offering expected to close?

The offering is expected to close on or about August 21, 2026, subject to customary closing conditions. According to QTREX Quantum, completion depends on satisfaction of these standard conditions, after which the company will receive the proceeds from the sale of the new ordinary shares.

How will QTREX Quantum (QTEX) use the proceeds from its $10 million registered direct offering?

QTREX Quantum plans to use the net proceeds for working capital and general corporate purposes. According to QTREX Quantum, the funds from the August 2026 registered direct offering will support ongoing operations across its advanced connectivity, electronics manufacturing, and medical technology activities.

Who is acting as placement agent for QTREX Quantum's August 2026 QTEX share offering?

A.G.P./Alliance Global Partners is serving as the sole placement agent for QTREX Quantum’s registered direct offering. According to QTREX Quantum, the ordinary shares are being sold via a prospectus supplement and base prospectus under its effective Form F-3 shelf registration statement filed with the U.S. SEC.